Altimmune (ALT) Receivables (2010 - 2026)

Altimmune (ALT) has reported Receivables for 17 consecutive years, with $3.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Receivables rose 237.93% year-over-year to $3.1 million; the TTM figure through Mar 2026 stood at $3.1 million (up 237.93% YoY), while the FY2025 annual figure was $2.3 million, up 145.66% from the prior year.
• Receivables climbed to $3.1 million in Q1 2026 per ALT's latest filing, from $2.3 million in the prior quarter.
• Across five years, Receivables topped out at $3.1 million in Q1 2026 and bottomed at $136000.0 in Q2 2023.
• Historically, Receivables has averaged $866411.8 across 5 years, with a median of $724000.0 in 2024.
• Annual changes were most pronounced in 2022 — Receivables slumped 95.98% — and 2023, when it jumped 600.0%.
• Altimmune's Receivables stood at $173000.0 in 2022, then surged by 600.0% to $1.2 million in 2023, then dropped by 22.05% to $944000.0 in 2024, then soared by 145.66% to $2.3 million in 2025, then soared by 32.17% to $3.1 million in 2026.
• Business Quant data shows ALT's Receivables at $3.1 million in Q1 2026, $2.3 million in Q4 2025, and $1.5 million in Q3 2025.